Research programme: interferon therapy - PBL Therapeutics
Alternative Names: Ultra interferonsLatest Information Update: 16 Jul 2016
At a glance
- Originator PBL Therapeutics
- Class Interferons
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Viral infections
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural)
- 14 Jul 2004 Ultra interferon™ is available for licensing in the treatment of severe acute respiratory syndrome (SARS) and for use against biodefense pathogens (http://www.pblbio.com)
- 11 Jul 2003 Preclinical trials in Cancer in USA (Intratumoural)